https://doi.org/10.55788/ad59ddcd
The phase 3 TRANSFORM-1 trial (NCT04472598) randomised 252 participants with untreated intermediate- or high-risk myelofibrosis and measurable splenomegaly to the Bcl-2 inhibitor navitoclax or placebo plus ruxolitinib. All participants received the JAK inhibitor ruxolitinib. The primary endpoint was a 35% spleen volume reduction (SVR35) at week 24 and Prof. Naveen Pemmaraju (MD Anderson Cancer Center, TX, USA) presented the findings [1].
The primary endpoint was met by 63% of the participants in the navitoclax arm and 32% in the placebo arm (P<0.0001). “This finding was consistent across subgroups,” highlighted Prof. Pemmaraju. Almost 50% of the included participants had high molecular risk profiles. In this subgroup of participants, the primary endpoint was met by 59% and 41%, favouring the navitoclax over the placebo arm. Also, variant allele frequency reductions of at least 20% at any time were seen in 57% of the navitoclax and 42% of the placebo receivers. Survival data was presented for the high molecular risk profile participants and the median progression-free survival was 25.2 months in the experimental arm versus 22.9 months in the placebo arm.
The most frequently occurring adverse events in the navitoclax arm were thrombocytopenia, anaemia, diarrhoea, and neutropenia, all observed in >30% of the participants. Finally, serious adverse events were seen in 28% of the participants on navitoclax and 38% on placebo.
Navitoclax plus ruxolitinib resulted in a 2-fold improvement of SVR35 at week 24 compared with placebo plus ruxolitinib in this population with myelofibrosis, without showing new safety signals.
- Pemmaraju N, et al. Efficacy and safety of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis in the phase 3 randomized, double-blind TRANSFORM-1 study. S222, EHA congress 2024, 13–16 June, Madrid, Spain.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for myelofibrosis? Next Article
The landscape of TP53 mutations and their prognostic impact in CLL »
« Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for myelofibrosis? Next Article
The landscape of TP53 mutations and their prognostic impact in CLL »
Table of Contents: EHA 2024
Featured articles
Meet the Expert: Prof. C. Ola Landgren discusses MRD as a key endpoint in haematological cancer trials
Multiple Myeloma
Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial
PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM
Post-intensification data confirm superiority of quadruple therapy in MM
Promising phase 1 results for novel CAR T-cell therapy in MM
DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM
Leukaemia
PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL
APOLLO: ATRA plus ATO meets expectations in high-risk APL
Excellent phase 3 results for asciminib in chronic myeloid leukaemia
AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy
FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML
CD40/CD47 inhibitor shows promise in high-risk MDS and AML
ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS
Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?
Can WGTS replace standard-of-care diagnostics in AML?
Non-malignant Haematology
ENERGIZE: Mitapivat meets primary efficacy endpoint in thalassaemia
Sovleplenib delivers durable responses and QoL improvements in primary ITP
Avatrombopag successful in children with chronic ITP
RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease
Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis
Myelofibrosis
Navitoclax plus ruxolitinib leads to spleen volume reductions in myelofibrosis
Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for myelofibrosis?
Lymphoma
The landscape of TP53 mutations and their prognostic impact in CLL
Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL?
High survival rates following atezolizumab consolidation in DLBCL
First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL
EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation
Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes
ECHO: Can we expect a novel standard of care in newly diagnosed MCL?
Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups
Related Articles
August 28, 2020
Nivolumab/brentuximab vedotin in R/R HL: good CMR rates
February 9, 2021
Anti-CD20 therapy for lymphoma tied to worse COVID-19 outcomes
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com